Adial Pharmaceuticals Welcomes Congressional Directive to Advance Alternative Clinical Trial Endpoints for Substance Use Disorders, Enhancing Regulatory Path for AD04 Therapy.

Adial Pharmaceuticals applauds Congressional directive to advance alternative clinical trial endpoints for substance use disorders, strengthening regulatory path for AD04. The directive, which aligns with the company's lead investigational therapy, AD04, aims to establish endpoints beyond abstinence that demonstrate meaningful clinical benefit, such as reduced cravings or disorder severity. This non-abstinence-based approach is expected to modernize regulatory expectations and support innovation in AUD treatment.